title: Three years of promise, proposals, and progress on optimizing the benefit/risk of medicines: a commentary on the 3rd FDA-DIA-PWG-PhRMA-BIO pharmacogenomics workshop.
authors.affiliation: Worldwide Regulatory Affairs, Pharma & Translational Medicine, Wyeth Research, Collegeville, PA 19454, USA. salernr@wyeth.com
authors.forename: R A
authors.initials: RA
authors.lastname: Salerno
authors.forename: L J
authors.initials: LJ
authors.lastname: Lesko
mesh_terms: D015195:Drug Design; D004345:Drug Industry / Q000592:standards / Q000639:trends; D005819:Genetic Markers; D010597:Pharmacogenetics / Q000592:standards / Q000639:trends; D018570:Risk Assessment; D014481:United States; D014486:United States Food and Drug Administration
chemical_list: D005819:Genetic Markers